CDNA250117C30000
- 0.05
- 0.000.00%
CareDx Newsroom
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
TC Biopharm Partners With CareDx For ACHIEVE Phase II Study
Express News | Tcbp Partners With CareDx to Support Achieve Clinical Trial Using Allocell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
TCBP Partners With CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
Possible Bearish Signals With CareDx Insiders Disposing Stock
Higher-Than-Anticipated Reimbursement Rates Lifted CareDx (CDNA)
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know
Transplant Therapeutics Consortium Receives FDA Acceptance of the Qualification Plan for IBox Scoring System
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
CareDx to Participate in Upcoming Investor Conferences
Accelerated Testing Volume Lifted CareDx (CDNA) in Q3
Q3 2024 CareDx Inc Earnings Call
Earnings Call: CareDx Sees Robust Growth in Q3, Raises FY 2024 Outlook
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating, Announces Target Price $40
CareDx, Inc's (NASDAQ:CDNA) 26% Dip In Price Shows Sentiment Is Matching Revenues
BTIG Maintains CareDx(CDNA.US) With Buy Rating, Cuts Target Price to $35
H.C. Wainwright Maintains CareDx(CDNA.US) With Hold Rating
CareDx: Strong Financial Performance and Strategic Positioning Support Buy Rating Amid Positive Long-Term Growth Prospects